CU20120048A7 - Composiciones y métodos para tratar infecciones bacterianas utilizando ceftarolina - Google Patents

Composiciones y métodos para tratar infecciones bacterianas utilizando ceftarolina

Info

Publication number
CU20120048A7
CU20120048A7 CU2012000048A CU20120048A CU20120048A7 CU 20120048 A7 CU20120048 A7 CU 20120048A7 CU 2012000048 A CU2012000048 A CU 2012000048A CU 20120048 A CU20120048 A CU 20120048A CU 20120048 A7 CU20120048 A7 CU 20120048A7
Authority
CU
Cuba
Prior art keywords
ceftaroline
compositions
methods
bacterial infections
treat bacterial
Prior art date
Application number
CU2012000048A
Other languages
English (en)
Inventor
Dirk Thye
George Talbot
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120048(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CU20120048A7 publication Critical patent/CU20120048A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden ceftarolina o un profármaco de esta (p. ej., ceftarolina fosamilo) y métodos para tratar infecciones bacterianas, tales como infecciones complicadas de la piel y sus estructuras (cSSSI), y la neumonía bacteriana adquirida en la comunidad (NBAC), administrando ceftarolina o un profármaco de esta (p. ej., ceftarolina fosamilo).
CU2012000048A 2009-09-21 2012-03-21 Composiciones y métodos para tratar infecciones bacterianas utilizando ceftarolina CU20120048A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14
PCT/US2010/049659 WO2011035305A1 (en) 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline

Publications (1)

Publication Number Publication Date
CU20120048A7 true CU20120048A7 (es) 2012-10-15

Family

ID=43757152

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000048A CU20120048A7 (es) 2009-09-21 2012-03-21 Composiciones y métodos para tratar infecciones bacterianas utilizando ceftarolina

Country Status (24)

Country Link
US (2) US20110071114A1 (es)
EP (1) EP2480236A4 (es)
KR (1) KR20120083344A (es)
CN (1) CN102781451A (es)
AU (1) AU2010295269B2 (es)
BR (1) BR112012006250B1 (es)
CA (1) CA2774772A1 (es)
CL (1) CL2012000694A1 (es)
CO (1) CO6531417A2 (es)
CR (1) CR20120137A (es)
CU (1) CU20120048A7 (es)
DO (1) DOP2012000077A (es)
EA (1) EA029149B1 (es)
EC (1) ECSP12011739A (es)
GT (1) GT201200082A (es)
HN (1) HN2012000585A (es)
IL (1) IL218349A0 (es)
MX (2) MX2012003201A (es)
NI (1) NI201200045A (es)
PE (2) PE20171176A1 (es)
PH (1) PH12012500528A1 (es)
SG (1) SG178936A1 (es)
WO (1) WO2011035305A1 (es)
ZA (1) ZA201202924B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
TWI565706B (zh) 2011-06-17 2017-01-11 阿斯特捷利康公司 用於製備包括反－７－酮基－６－（磺酸氧基）－１，６－二氮雜雙環［３，２，１］辛烷－２－甲醯胺之雜環化合物及其鹽類之方法
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
DK1310502T3 (da) * 2000-08-10 2009-09-07 Takeda Pharmaceutical Phosphonocephem-forbindelse
WO2002093162A2 (en) * 2001-05-17 2002-11-21 Mcgill University Individualization of therapy with antibiotic agents
IL163666A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2008302201A1 (en) * 2007-09-21 2009-03-26 Astrazeneca Ab Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Also Published As

Publication number Publication date
MX2012003411A (es) 2012-04-30
ZA201202924B (en) 2012-12-27
NI201200045A (es) 2012-11-02
US20150258126A1 (en) 2015-09-17
US20110071114A1 (en) 2011-03-24
EP2480236A4 (en) 2013-04-17
WO2011035305A1 (en) 2011-03-24
IL218349A0 (en) 2012-04-30
CO6531417A2 (es) 2012-09-28
ECSP12011739A (es) 2012-05-30
AU2010295269B2 (en) 2014-06-05
MX2012003201A (es) 2012-05-08
EA029149B1 (ru) 2018-02-28
EP2480236A1 (en) 2012-08-01
PH12012500528A1 (en) 2019-06-14
HN2012000585A (es) 2015-06-15
AU2010295269A1 (en) 2012-04-12
CL2012000694A1 (es) 2012-08-31
CN102781451A (zh) 2012-11-14
DOP2012000077A (es) 2012-05-31
US9629861B2 (en) 2017-04-25
BR112012006250A2 (pt) 2016-05-31
CR20120137A (es) 2012-05-28
EA201200501A1 (ru) 2012-10-30
GT201200082A (es) 2014-12-22
SG178936A1 (en) 2012-04-27
BR112012006250B1 (pt) 2021-07-06
PE20121819A1 (es) 2013-02-01
CA2774772A1 (en) 2011-03-24
PE20171176A1 (es) 2017-08-22
KR20120083344A (ko) 2012-07-25

Similar Documents

Publication Publication Date Title
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
CR20120264A (es) Compuestos
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
BR112012020693A8 (pt) Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
ECSP11011276A (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma.
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
ECSP11011436A (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
MX2019003738A (es) Compuestos antivirales.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
GT201400097A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
EA201170832A1 (ru) Пуриновые соединения
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2011009847A (es) Agentes antihelminticos y su uso.
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
CR20130602A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
CO6450617A2 (es) Produccion de hidrocarburos de isopreno mejorada que usa cianobacterias diseñadas geneticamente
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
PH12012501963A1 (en) Compositions and methods for the diagnosis and treatment of tumor
BR112014026817A2 (pt) derivados do pantotenato para o tratamento de transtornos neurológicos
ECSP12011739A (es) Composiciones y métodos para tratar infecciones bacterianas utilizando ceftarolina
BR112014017587A8 (pt) métodos e formulações para o tratamento de deficiências de ácido siálico